BridgeMD
Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane (CASUAL ECMO)
EU CTIS ID: 2024-518702-40-00
What this study is testing
The primary outcome of this study will be to assess the difference in the occurrence of thromboembolic events during ECMO therapy depending on the three different anticoagulants used. The comparison will be calculated between both the low-molecular heparin (LMWH) Enoxaparin as well as the direct thrombin inhibitor (DTI) Argatroban and the current recommendation of the ELSO unfractionated heparin (UFH).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- atients at the following ICUs of the MUV (13C1, 13C2, 9D, 13B1, 13I1, A7) will be included if they are older than 18 years and either • require ECMO support or • have been started on ECMO therapy within the last 12 hours
You likely can't join if
- Patients exhibiting contraindications to anticoagulation in general or any of the three investigated substances, including clinician’s decision to conduct ECMO support without anticoagulation due to extreme bleeding risk or if the clinician determines that the patient’s condition necessitates a specific approach to anticoagulation during ECMO support • Patients who are pregnant • Patients suffering from a clinically relevant pre-existing coagulopathy • Patients, for whom screening, randomization and implementation of study protocol cannot be initiated within 12 hours after cannulation • Patients receiving ongoing therapeutic systemic anticoagulation prior to ECMO implantation, or exhibiting an indication for therapeutic anticoagulation (e.g., pulmonary embolism) • Patients whose total duration of ECMO support lasts less than 24 hours • Patients with start of ECMO support during CPR (eCPR) • Patients with passive decarboxylation, without an active pumping system • Patients, who have been weaned off ECMO support within the last 30 days • Patients with central ECMO cannulation and/or after cardiopulmonary bypass
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.